Viewing Study NCT00603668

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 5:53 PM

Ignite Modification Date: 2026-01-09 @ 1:13 PM

Study NCT ID: NCT00603668

Status: COMPLETED

Last Update Posted: 2021-08-16

First Post: 2008-01-08

Is Gene Therapy: True

Has Adverse Events: False

Brief Title: Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL

Sponsor: Gilead Sciences

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module